Literature DB >> 28811972

Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death.

Ruan F V Medrano1, Aline Hunger1, João P P Catani1, Bryan E Strauss1.   

Abstract

Simultaneous reestablishment of p53/p19Arf and interferon-β pathways in melanoma cells culminates in a cell death process that displays features of necroptosis along with the release of immunogenic cell death molecules and unleashes an antitumor immune response mediated by natural killer cells, neutrophils as well as CD4+ and CD8+ T lymphocytes.

Entities:  

Keywords:  Adenovirus; gene therapy; immunogenic cell death; immunotherapy; melanoma; p53

Year:  2017        PMID： 28811972      PMCID： PMC5543818          DOI： 10.1080/2162402X.2017.1329072

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  30 in total

1.  p53-independent functions of the p19(ARF) tumor suppressor.

Authors:  J D Weber; J R Jeffers; J E Rehg; D H Randle; G Lozano; M F Roussel; C J Sherr; G P Zambetti
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

2.  Quantifying the relationship between multiple immunological parameters and host resistance: probing the limits of reductionism.

Authors:  D Keil; R W Luebke; S B Pruett
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

3.  Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.

Authors:  Rodrigo Esaki Tamura; Rafael Bento da Silva Soares; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

4.  Type I interferon-mediated immune response against influenza A virus is attenuated in the absence of p53.

Authors:  Zixiang Zhu; Yifan Yang; Jianchao Wei; Donghua Shao; Zixue Shi; Beibei Li; Ke Liu; Yafeng Qiu; Haixue Zheng; Zhiyong Ma
Journal:  Biochem Biophys Res Commun       Date:  2014-10-22       Impact factor: 3.575

5.  Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia.

Authors:  A Coleman; J W Fountain; T Nobori; O I Olopade; G Robertson; D E Housman; T G Lugo
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

6.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

7.  Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.

Authors:  Ruan Felipe Vieira Medrano; João Paulo Portela Catani; Aline Hunger Ribeiro; Samanta Lopes Tomaz; Christian A Merkel; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Cancer Immunol Immunother       Date:  2016-02-18       Impact factor: 6.968

8.  Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines.

Authors:  Raudel Sandoval; Jiaping Xue; Mark Pilkinton; Debra Salvi; Hiroaki Kiyokawa; Oscar R Colamonici
Journal:  J Biol Chem       Date:  2004-05-28       Impact factor: 5.157

9.  Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.

Authors:  João Paulo Portela Catani; Ruan F V Medrano; Aline Hunger; Paulo Del Valle; Sandy Adjemian; Daniela Bertolini Zanatta; Guido Kroemer; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Transl Oncol       Date:  2016-12       Impact factor: 4.243

10.  CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection.

Authors:  Namir Shaabani; Vikas Duhan; Vishal Khairnar; Asmae Gassa; Rita Ferrer-Tur; Dieter Häussinger; Mike Recher; Gennadiy Zelinskyy; Jia Liu; Ulf Dittmer; Mirko Trilling; Stefanie Scheu; Cornelia Hardt; Philipp A Lang; Nadine Honke; Karl S Lang
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469
View more
  6 in total

Review 1.  Non-Apoptotic Cell Death Signaling Pathways in Melanoma.

Authors:  Mariusz L Hartman
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

2.  p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro.

Authors:  R C Da-Costa; I L Vieira; A Hunger; R E Tamura; B E Strauss
Journal:  Braz J Med Biol Res       Date:  2020-02-14       Impact factor: 2.590

Review 3.  Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.

Authors:  Xiangyu Deng; Zengwu Shao; Yanli Zhao
Journal:  Adv Sci (Weinh)       Date:  2021-01-05       Impact factor: 16.806

Review 4.  Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.

Authors:  Otto Luiz Dutra Cerqueira; Fernanda Antunes; Nadine G Assis; Elaine C Cardoso; Maria A Clavijo-Salomón; Ana C Domingues; Nayara G Tessarollo; Bryan E Strauss
Journal:  Front Mol Biosci       Date:  2022-04-14

5.  Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy.

Authors:  Ruan F V Medrano; Thiago A Salles; Rafael Dariolli; Fernanda Antunes; Valker A Feitosa; Aline Hunger; João P P Catani; Samir A Mendonça; Rodrigo E Tamura; Marlous G Lana; Elaine G Rodrigues; Bryan E Strauss
Journal:  Sci Rep       Date:  2022-08-10       Impact factor: 4.996

Review 6.  Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer.

Authors:  Bryan E Strauss; Gissele Rolemberg Oliveira Silva; Igor de Luna Vieira; Otto Luiz Dutra Cerqueira; Paulo Roberto Del Valle; Ruan Felipe Vieira Medrano; Samir Andrade Mendonça
Journal:  Clinics (Sao Paulo)       Date:  2018-09-06       Impact factor: 2.365
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.